Na+ CP type II alpha, Polyclonal Antibody

SCN2A; Brain sodium channel type II; BFIC3; BFNIS; EIEE11; HBSC II; HBSCI; Na(v)1.2; NachII; SCN2A2; ScpII; BFIS3; HBA; HBSCII; NAC2; Nav1.2; RNSCPIIR; SCN2A1

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit

Na+ CP type II alpha Antibody detects endogenous levels of total Na+ CP type II alpha

Immunogen affinity purified

Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

1.0mg/mL (lot specific)

Store at -20 degree C

Small volumes of anti-Na+ CP type II alpha antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Total protein Ab

Western Blot (WB)

Western Blot: 1:1000-3000

Western blot analysis Na+ CP type II alpha using Jurkat whole cell lysates

sodium voltage-gated channel alpha subunit 2

sodium channel protein type 2 subunit alpha

Sodium channel protein type 2 subunit alpha

NAC2; SCN2A1; SCN2A2  [Similar Products]

SCN2A_HUMAN

Voltage-gated sodium channels are transmembrane glycoprotein complexes composed of a large alpha subunit with four repeat domains, each of which is composed of six membrane-spanning segments, and one or more regulatory beta subunits. Voltage-gated sodium channels function in the generation and propagation of action potentials in neurons and muscle. This gene encodes one member of the sodium channel alpha subunit gene family. Allelic variants of this gene are associated with seizure disorders and autism spectrum disorder. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2016]

SCN2A: Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. Defects in SCN2A are the cause of seizures, benign familial infantile type 3 (BFIS3). An autosomal dominant disorder in which afebrile seizures occur in clusters during the first year of life, without neurologic sequelae. Defects in SCN2A are the cause of epileptic encephalopathy early infantile type 11 (EIEE11). EIEE11 is an autosomal dominant seizure disorder characterized by infantile onset of refractory seizures with resultant delayed neurologic development and persistent neurologic abnormalities. Belongs to the sodium channel (TC 1.A.1.10) family. Nav1.2/SCN2A subfamily. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Channel, sodium; Membrane protein, integral; Membrane protein, multi-pass

Chromosomal Location of Human Ortholog: 2q24.3

Cellular Component: axon; integral to plasma membrane; intrinsic to plasma membrane

Molecular Function: voltage-gated sodium channel activity

Biological Process: generation of action potential; myelination; sodium ion transport

Disease: Epileptic Encephalopathy, Early Infantile, 11; Seizures, Benign Familial Infantile, 3

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.